Related Experiment Video

Updated: Jun 8, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events

Gennaro Galasso1, Gaetano Santulli, Federico Piscione

  • 1Department of Clinical Medicine, Cardiovascular and Immunologic Sciences, Federico II University School of Medicine, Naples, Italy.

BMC Cardiovascular Disorders
|September 18, 2010
PubMed

Insights

The PlA2 polymorphism is linked to increased risks of cardiac death, myocardial infarction, and stroke in patients with atherosclerosis. This genetic factor independently predicts major adverse cardiac events and cerebrovascular events.

Area of Science:

  • Genetics
  • Cardiology
  • Neurology

Background:

  • The role of PlA2 polymorphism in thrombotic cardiovascular complications remains unclear.
  • Previous studies have yielded conflicting results regarding its clinical impact.

Purpose of the Study:

  • To investigate the effect of PlA2 polymorphism on outcomes in patients with atherosclerosis.
  • To determine if PlA2 allele presence is associated with thrombotic cardiovascular events.

Main Methods:

  • A study of 400 coronary artery disease patients undergoing percutaneous coronary intervention.
  • A replication study in 74 hypertensive patients with cerebrovascular events and 100 healthy controls.
  • PlA genotype determined by PCR-RFLP; major adverse cardiac events (MACE) recorded over a mean follow-up of 24 months.

Main Results:

  • PlA2 allele presence associated with higher cardiac death (13.1% vs 1.5%), myocardial infarction (10.7% vs 2.6%), and revascularization needs (34.8% vs 17.7%) in CAD patients.
  • Kaplan-Meier analysis showed worse long-term outcome for patients with PlA2 allele (p=0.015).
  • PlA2 independently predicted cardiac death (OR: 9.594) and MACE (OR: 1.829); increased stroke risk (OR: 4.1) in replication study.

Conclusions:

  • The PlA2 allele is associated with an increased risk of thrombotic cardiovascular complications in patients with severe atherosclerosis.
  • PlA2 polymorphism serves as an independent predictor for adverse cardiovascular and cerebrovascular events.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...